Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Share-based Compensation (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Share-based Compensation data on record, last reported at $5.0 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 26.84% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $21.5 million, up 57.93%, while the annual FY2025 figure was $21.5 million, 57.93% up from the prior year.
  • Share-based Compensation reached $5.0 million in Q4 2025 per PLSE's latest filing, down from $5.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.8 million in Q4 2024 and bottomed at $723000.0 in Q3 2022.
  • Average Share-based Compensation over 5 years is $3.1 million, with a median of $2.5 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: tumbled 79.29% in 2022, then surged 347.06% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $3.6 million in 2021, then crashed by 79.29% to $748000.0 in 2022, then soared by 347.06% to $3.3 million in 2023, then soared by 103.14% to $6.8 million in 2024, then decreased by 26.84% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $5.0 million in Q4 2025, $5.6 million in Q3 2025, and $5.2 million in Q2 2025.